patent.fyi
Applications  /  US 2026/0355137
United States Patent Application Publication

US 2026/0355137 A1

Published
Nov 12, 2026
Filed
Nov 20, 2023
Earliest date on the face
Nov 18, 2022
Classification
A61K 31/192
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Prostaglandin mediated aqueous outflow

What ifWhat if the pressure-lowering active ingredient were a prostaglandin ester prodrug?
Claim language“Cinnamic acids or its derivatives”

Corneal esterases hydrolyze the prodrug after topical instillation. The released acid activates prostaglandin F receptors and increases uveoscleral aqueous humor outflow.

1.1Carbonic anhydrase inhibition

What ifWhat if the pressure-lowering active ingredient were a sulfonamide carbonic anhydrase inhibitor?
Claim language“Cinnamic acids or its derivatives”

A buffered aqueous drop delivers the dissolved inhibitor to the anterior segment. Inhibition of carbonic anhydrase in the ciliary epithelium reduces bicarbonate formation and aqueous humor secretion.

1.1Glucocorticoid receptor activation

What ifWhat if the anti-inflammatory active ingredient were a glucocorticoid phosphate salt?
Claim language“Cinnamic acids or its derivatives”

The water-soluble phosphate salt forms a clear aqueous solution. Tissue phosphatases release the glucocorticoid, which activates intracellular receptors and reduces expression of inflammatory mediators.

1.2Beta receptor blockade

What ifWhat if the pressure-lowering active ingredient were a beta-adrenergic receptor antagonist?
Claim language“Catechins or its derivatives”

A buffered aqueous drop carries a soluble salt of the antagonist. Beta receptor blockade in the ciliary epithelium reduces aqueous humor production.

1.2Cyclooxygenase inhibition after hydrolysis

What ifWhat if the anti-inflammatory active ingredient were an arylacetic acid amide prodrug?
Claim language“Catechins or its derivatives”

A micronized suspension disperses solid prodrug particles in an aqueous vehicle. Ocular hydrolases convert dissolved prodrug to the corresponding arylacetic acid, which inhibits cyclooxygenase and reduces prostaglandin synthesis.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Perfusion medium for excised corneas

An ex vivo corneal test fixture uses a buffered medium containing catechin on the epithelial side of an excised cornea. A clamping ring holds the cornea between the epithelial chamber and a separate receiver chamber. A pump feeds fresh medium through the epithelial chamber, and an outlet carries spent medium to a collection vessel. Samples from the receiver chamber track catechin transport across the tissue.

Component substitution

Chlorogenic acid replaces free caffeic acid

Chlorogenic acid, an ester of caffeic acid and quinic acid, replaces free caffeic acid as the cinnamic acid component. The ester dissolves in an aqueous buffer, and a tonicity adjuster sets the osmolality of the solution before filtration. Liquid chromatography with ultraviolet detection measures both the ester and free caffeic acid in samples taken during storage.

Parameter or scale variation

Metered drops at two volumes

A benchtop fixture mounts interchangeable positive-displacement heads on the same reservoir of catechin solution. The heads deliver nominal volumes of 10 and 30 microliters to a curved corneal model at 60-second intervals. A balance measures delivered volume by mass and solution density, and a collection tray captures runoff for comparison between the two settings.

Combination with existing systems

Catechin reservoir in a scleral lens

A rigid gas-permeable scleral lens vaults the cornea and rests on the surrounding sclera. A sterile, preservative-free, isotonic catechin solution fills the lens bowl before placement. The space between the back surface of the lens and the cornea holds the solution against the corneal surface while the lens is in place.

Two chamber cartridge for on demand mixing

A single-use cartridge holds a dry catechin preparation in one chamber and sterile buffered diluent in a second chamber. A frangible seal separates the chambers until a plunger drives diluent into the dry chamber. The operator inverts the cartridge to dissolve the solids, then dispenses the mixed solution through an integral drop tip.

Automated or data-driven variant

Automated monitoring of catechin degradation

An autosampler draws samples from retained units of a catechin ophthalmic solution at scheduled storage intervals. A liquid chromatograph separates catechin from its degradation products, and an ultraviolet detector records the peaks. Software calculates catechin concentration from a calibration curve and flags samples that cross preset limits for active concentration or degradation peak area.

Specific version of a part

Caffeic acid aqueous solution

Caffeic acid, a dihydroxycinnamic acid, serves as the active ingredient in a buffered aqueous drop. Partial neutralization with sodium hydroxide increases the fraction present as dissolved caffeate.

Ferulic acid cyclodextrin solution

Ferulic acid, a hydroxy-methoxycinnamic acid, serves as the active ingredient in an aqueous vehicle containing hydroxypropyl beta-cyclodextrin. Reversible inclusion complex formation increases the amount of ferulic acid held in solution.

Epicatechin aqueous drop

Epicatechin serves as the dissolved active ingredient in a citrate-buffered aqueous drop. Sodium chloride adjusts tonicity, and a light-blocking single-dose container limits light exposure during storage.

Epigallocatechin gallate liposomal dispersion

Epigallocatechin gallate, a gallate ester of a catechin, serves as the active ingredient in a phosphatidylcholine liposome dispersion. The liposomes are suspended in a buffered aqueous vehicle, and encapsulated solute is released as it partitions into the surrounding fluid.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 10,100,036 B2
Published
Oct 16, 2018
Filed
Sep 25, 2017
Class
C07D 401/12
Document BUS 2022/0105054 A1
Published
Apr 7, 2022
Filed
Sep 28, 2021
Class
A61K 31/12
Claim 1
Document A
Document B
1.1i. Cinnamic acids or its derivatives as active ingredients; and/or
Cinnamic acid, aza-cinnamic acid and their derivatives have antitumor activities.
A · US 10,100,036 B2 · ¶ 8
The absorption enhancer according to the present embodiment may further contain at least one selected from the group consisting of the cinnamic acid derivatives represented by formula (1) or (2) in addition to curcumin as an active ingredient.
B · US 2022/0105054 A1 · ¶ 23
1.2ii. Catechins or its derivatives as active ingredients.

An empty cell means only that no passage was reproduced there.

Statements in these documents
The present invention relates to the field of medicinal chemistry, and in particular, to lappaconitine aza-cinnamic acid derivatives having antitumor activities and a method of preparing the same
A · US 10,100,036 B2 · ¶ 2
There remains a need for effective and safe small molecular anti-tumor drugs.
A · US 10,100,036 B2 · ¶ 9
Therefore, it is desirable to be able to absorb the cinnamic acid derivatives into the body more efficiently even when the intake thereof is small.
B · US 2022/0105054 A1 · ¶ 4
An object of the present invention is to provide an agent capable of enhancing absorption of a cinnamic acid derivative having a specific structure into the body.
B · US 2022/0105054 A1 · ¶ 5
Cite aspatent.fyi, US 2026/0355137 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355137/, SHA-256 84b8efcf9ea7d24a480a39ec950c313aec5518ba8523f5c76e67f0a953baec5b
First published
Permanent addresshttps://patent.fyi/US20260355137/
Content fingerprint (SHA-256)84b8efcf9ea7d24a480a39ec950c313aec5518ba8523f5c76e67f0a953baec5b
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi